FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036699073> ?p ?o ?g. }

• W3036699073 endingPage "688" @default.
• W3036699073 startingPage "688" @default.
• W3036699073 abstract "Abstract Background and hypothesis: Infancy is a critical time during which the first complications of sickle cell anemia (SCA) emerge. Very early prognostic factors of severity are needed to select high-risk children to offer precisely tailored therapy. Our hypothesis was that clinical, biological or genetic parameters measurable soon after birth (3 to 6 months of age) could predict severe outcomes in the first two years of life in SCA infants. Methods: Infants with SCA were offered to participate in a prospective study (ClinicalTrials.gov: NCT01207037) that included clinical and laboratory assessment at enrollment (3-6 months) and at 12, 18 and 24 months of age. The prognostic performance of conventional and SCA-specific biomarkers (notably erythroid adhesion markers, dense cells, ektacytometry indices) on disease severity was assessed using Cox's proportional hazard regression models. The disease severity was defined as time to first occurrence of either acute splenic sequestration (ASS), vaso occlusive (VOC) event requiring hospitalization, transfusion, conditional or abnormal Trans Cranial Doppler, acute chest syndrome and death. Hazard ratios (HRs) were calculated with 95% Cis. Results: Fifty-seven infants (55 SS; 2 Sβ°; 54.4% males), diagnosed through neonatal screening, were included in the study at a mean age of 4.4 ± 1 months and longitudinally assessed with a median follow-up of 19.4 months (range 3.1-23.2). Only 1 of 57 infants had experienced a SCA-related event prior to enrolment (dactilytis). At inclusion, clinical examinations were unremarkable except for pallor found in 15 (26,3%) and none of the infants had an enlarged or palpable spleen. Growth parameters were normal. Main biological characteristics were a mild hemolytic anemia (Hb 9.3 ±1.3 g/dL; reticulocytes count: 151.2 ±76 x 109/L), increased HbF level (3.8 ±1.3 g/dL. or 41.4 ±11.7%) and presence of dense red cells (23.1 % ±10.8). Genetic analysis showed one alpha globin deletion in 18 (32.1%) and a balanced distribution of beta globin haplotypes: 16 (30.8%), 18 (34.6%) and 18 (34.6%) in the favorable (SEN/SEN, BEN/SEN, CAM/SEN or SEN/ATYP), unfavorable (CAR/CAR, CAM/CAR, CAR/ATYP or BEN/CAR) and intermediate category (other) respectively. During the 2 years duration of the study, 44 of 57 (77%) infants required 157 hospital admissions, median (range): 2 (1-12) per patient. Infection was a leading cause of hospitalization although no serious adverse event related to pneumococcal infection was noted. Eight (14%) children experienced an episode of ASS at a median (range) age of 13.4 months (7.8- 15.9) while 13 infants (22.8%) experienced at least one VOC event at a median age of 12.7 months (7-22.5), with 6 experiencing ≥ 2 episodes. Nineteen infants (33.3%) required at least one transfusion with 10 (17.6%) requiring more than 2. Altogether, 22 (38.6%) infants of this cohort experienced a SCA-related severe clinical event by 24 months of age. The Kaplan Meier estimate of the 24-month event-free rate was 54.4% (95% CI, 39.7 to 74.5%) (Figure). Univariate analysis of potential prognostic markers at inclusion showed that higher HbF % and concentration were the strongest protective parameters for ASS in particular and for all severe outcomes, except for VOC (p &lt; 0.001). Unfavorable haplotypes were also associated with severe outcome (HR (95% CI) 4.73 (1.31-17.01), p=0.017). Protective factors for VOC were higher Hb level (threshold &gt; 8 g/dL) and low % of circulating dense cells (p=0.04 and 0.02, respectively). In a multivariate analysis, Hb level ≥ 8 g/dL and HbF ≥ 2.8 g/dL proved to be two independent prognostic factors of a SCA-related severe event (adjusted HRs (95% CI) 0.27 (0.11-0.73) and 0.16 (0.06-0.43) respectively). Interestingly, absolute neutrophil or reticulocyte counts, level of expression of known potentially pathogenic erythroid adhesion markers (CD36, Lu/B-CAM, ICAM-4/LW), % of red dense cell, or deformability parameters failed to be prognostic factors of specific complications or overall severity in this very young cohort. Conclusion: HbF and Hb levels measured between 3 and 6 months of age in SCA infants predict the risk of subsequent severe clinical outcome in the next 2 years. These events are frequent even in a high-income setting where neonatal screening is implemented. These findings further support the early use of HbF inducers such as hydroxyurea in high-risk infants to sustain a protective HbF level. Figure 1 Figure 1. Disclosures Brousse: Add Medica: Membership on an entity's Board of Directors or advisory committees. De Montalembert: Novartis: Consultancy, Honoraria, Research Funding; Addmedica: Consultancy, Honoraria, Research Funding." @default.
• W3036699073 created "2020-06-25" @default.
• W3036699073 creator A5007220235 @default.
• W3036699073 creator A5008011056 @default.
• W3036699073 creator A5013341235 @default.
• W3036699073 creator A5019836697 @default.
• W3036699073 creator A5022121572 @default.
• W3036699073 creator A5023445306 @default.
• W3036699073 creator A5029453857 @default.
• W3036699073 creator A5029545816 @default.
• W3036699073 creator A5033760104 @default.
• W3036699073 creator A5034746599 @default.
• W3036699073 creator A5040895843 @default.
• W3036699073 creator A5041630751 @default.
• W3036699073 creator A5042640180 @default.
• W3036699073 creator A5045141267 @default.
• W3036699073 creator A5053014054 @default.
• W3036699073 creator A5065889464 @default.
• W3036699073 creator A5066992499 @default.
• W3036699073 creator A5073701453 @default.
• W3036699073 creator A5076084805 @default.
• W3036699073 creator A5080988958 @default.
• W3036699073 creator A5081997459 @default.
• W3036699073 creator A5088680060 @default.
• W3036699073 creator A5089598609 @default.
• W3036699073 date "2017-12-07" @default.
• W3036699073 modified "2023-10-17" @default.
• W3036699073 title "The First Two Years of Life in Sickle Cell Anemia Infants: Results of a Comprehensive Longitudinal Study" @default.
• W3036699073 doi "https://doi.org/10.1182/blood.v130.suppl_1.688.688" @default.
• W3036699073 hasPublicationYear "2017" @default.
• W3036699073 type Work @default.
• W3036699073 sameAs 3036699073 @default.
• W3036699073 citedByCount "0" @default.
• W3036699073 crossrefType "journal-article" @default.
• W3036699073 hasAuthorship W3036699073A5007220235 @default.
• W3036699073 hasAuthorship W3036699073A5008011056 @default.
• W3036699073 hasAuthorship W3036699073A5013341235 @default.
• W3036699073 hasAuthorship W3036699073A5019836697 @default.
• W3036699073 hasAuthorship W3036699073A5022121572 @default.
• W3036699073 hasAuthorship W3036699073A5023445306 @default.
• W3036699073 hasAuthorship W3036699073A5029453857 @default.
• W3036699073 hasAuthorship W3036699073A5029545816 @default.
• W3036699073 hasAuthorship W3036699073A5033760104 @default.
• W3036699073 hasAuthorship W3036699073A5034746599 @default.
• W3036699073 hasAuthorship W3036699073A5040895843 @default.
• W3036699073 hasAuthorship W3036699073A5041630751 @default.
• W3036699073 hasAuthorship W3036699073A5042640180 @default.
• W3036699073 hasAuthorship W3036699073A5045141267 @default.
• W3036699073 hasAuthorship W3036699073A5053014054 @default.
• W3036699073 hasAuthorship W3036699073A5065889464 @default.
• W3036699073 hasAuthorship W3036699073A5066992499 @default.
• W3036699073 hasAuthorship W3036699073A5073701453 @default.
• W3036699073 hasAuthorship W3036699073A5076084805 @default.
• W3036699073 hasAuthorship W3036699073A5080988958 @default.
• W3036699073 hasAuthorship W3036699073A5081997459 @default.
• W3036699073 hasAuthorship W3036699073A5088680060 @default.
• W3036699073 hasAuthorship W3036699073A5089598609 @default.
• W3036699073 hasConcept C126322002 @default.
• W3036699073 hasConcept C187212893 @default.
• W3036699073 hasConcept C188816634 @default.
• W3036699073 hasConcept C207103383 @default.
• W3036699073 hasConcept C2778124894 @default.
• W3036699073 hasConcept C2778248108 @default.
• W3036699073 hasConcept C2778620579 @default.
• W3036699073 hasConcept C2779134260 @default.
• W3036699073 hasConcept C2780976302 @default.
• W3036699073 hasConcept C44249647 @default.
• W3036699073 hasConcept C50382708 @default.
• W3036699073 hasConcept C71924100 @default.
• W3036699073 hasConceptScore W3036699073C126322002 @default.
• W3036699073 hasConceptScore W3036699073C187212893 @default.
• W3036699073 hasConceptScore W3036699073C188816634 @default.
• W3036699073 hasConceptScore W3036699073C207103383 @default.
• W3036699073 hasConceptScore W3036699073C2778124894 @default.
• W3036699073 hasConceptScore W3036699073C2778248108 @default.
• W3036699073 hasConceptScore W3036699073C2778620579 @default.
• W3036699073 hasConceptScore W3036699073C2779134260 @default.
• W3036699073 hasConceptScore W3036699073C2780976302 @default.
• W3036699073 hasConceptScore W3036699073C44249647 @default.
• W3036699073 hasConceptScore W3036699073C50382708 @default.
• W3036699073 hasConceptScore W3036699073C71924100 @default.
• W3036699073 hasIssue "Suppl_1" @default.
• W3036699073 hasLocation W30366990731 @default.
• W3036699073 hasOpenAccess W3036699073 @default.
• W3036699073 hasPrimaryLocation W30366990731 @default.
• W3036699073 hasRelatedWork W1999097079 @default.
• W3036699073 hasRelatedWork W2013062939 @default.
• W3036699073 hasRelatedWork W2071046442 @default.
• W3036699073 hasRelatedWork W2286136647 @default.
• W3036699073 hasRelatedWork W2572837865 @default.
• W3036699073 hasRelatedWork W2894274090 @default.
• W3036699073 hasRelatedWork W3009252469 @default.
• W3036699073 hasRelatedWork W2350708333 @default.
• W3036699073 hasRelatedWork W2480594226 @default.
• W3036699073 hasRelatedWork W3088975555 @default.
• W3036699073 hasVolume "130" @default.
• W3036699073 isParatext "false" @default.
• W3036699073 isRetracted "false" @default.

• next